Physicians' Academy for Cardiovascular Education

GLP-1 agonist lowers CV biomarkers in high-risk T2DM patients

Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial

von Scholten BJ, Persson F, Rosenlund S, et al. - Diabetes Obes Metab. 2017; published online ahead of print


Type 2 diabetic (T2DM) patients are at high CVD risk, particularly those with albuminuria [1]. Liraglutide has glucose-lowering effects but also supports weight loss, lowers blood pressure (BP), albuminuria and lipid-levels. Moreover it is suggested that liraglutide may have anti-inflammatory and vasodilatory effects [2-4]. Endothelial dysfunction is an early marker of atherosclerosis, and inflammatory processes play an important role in atherosclerotic cardiovascular disease [5].

Therefore, it was hypothesised in current study that liraglutide treatment is associated with the reduction of inflammatory biomarkers and CV risk biomarkers in high-risk patients. To validate this, a randomised, double-blind, cross-over study was performed to evaluate the effect of liraglutide on five CVD-associated biomarkers in 27 T2DM patients with persistent albuminuria. For this, 12 weeks of treatment was followed by a 4-week washout period.

The biomarkers reflect different pathophysiology and included tumour necrosis factor-alpha (TNF-alpha), soluble urokinase plasminogen-activator-receptor (suPAR), mid-regional pro-adrenomedullin (MR-proADM), mid-regional pro-atrial natriuretic peptide (MR-proANP), and copeptin.

Main results


In T2DM patients with albuminuria, liraglutide treatment was associated with reductions in circulating levels of CV risk biomarkers TNF-alpha, MR-proADM and MR-proANP. These findings support the hypothesis that liraglutide treatment may be associated with the reduction of inflammatory and CV risk biomarkers in high-risk patients.


Show references

Find this article online at Diabetes Obes Metab